And the results showed that low/medium MAPK14 expression had a better survival probability than high MAPK14 expression of STAD patients (Extended data Fig. S4C), while ERBB3 expression did not show significant effect on survival probability of STAD patients (Extended data Fig. S4D). This evidence concerns the gene ERBB3 and gastric adenocarcinoma.